Equities research analysts expect that Elanco Animal Health (NYSE:ELAN) will announce earnings per share of $0.26 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Elanco Animal Health’s earnings, with the highest EPS estimate coming in at $0.27 and the lowest estimate coming in at $0.25. Elanco Animal Health reported earnings per share of $0.29 during the same quarter last year, which indicates a negative year-over-year growth rate of 10.3%. The firm is expected to report its next earnings report before the market opens on Wednesday, November 6th.

On average, analysts expect that Elanco Animal Health will report full year earnings of $1.08 per share for the current fiscal year, with EPS estimates ranging from $1.06 to $1.10. For the next financial year, analysts forecast that the firm will post earnings of $1.25 per share, with EPS estimates ranging from $1.22 to $1.30. Zacks’ EPS averages are an average based on a survey of analysts that cover Elanco Animal Health.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.02. The business had revenue of $781.60 million for the quarter, compared to analysts’ expectations of $781.49 million. Elanco Animal Health had a return on equity of 7.83% and a net margin of 4.69%. The firm’s revenue was up 1.5% compared to the same quarter last year.

ELAN has been the topic of a number of research reports. ValuEngine upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. UBS Group upgraded Elanco Animal Health from a “sell” rating to a “neutral” rating and dropped their price target for the stock from $31.00 to $30.00 in a research report on Thursday, August 15th. Barclays initiated coverage on Elanco Animal Health in a research report on Monday, September 23rd. They set an “overweight” rating and a $36.00 price target on the stock. Zacks Investment Research cut Elanco Animal Health from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Goldman Sachs Group initiated coverage on Elanco Animal Health in a research report on Monday, September 9th. They set a “positive” rating on the stock. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $33.63.

Shares of Elanco Animal Health stock traded down $0.24 on Friday, reaching $26.23. 2,419,200 shares of the company were exchanged, compared to its average volume of 5,492,348. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.71 and a current ratio of 3.07. The company’s 50-day moving average is $27.03 and its two-hundred day moving average is $30.86. The firm has a market cap of $9.93 billion and a price-to-earnings ratio of 22.23. Elanco Animal Health has a 1-year low of $25.51 and a 1-year high of $35.46.

In other news, Director Deborah Turner Kochevar purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, September 11th. The stock was purchased at an average cost of $27.95 per share, with a total value of $27,950.00. Also, CEO Jeffrey N. Simmons purchased 75,750 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average cost of $26.55 per share, with a total value of $2,011,162.50. Following the completion of the purchase, the chief executive officer now owns 470,006 shares in the company, valued at approximately $12,478,659.30. The disclosure for this purchase can be found here. Insiders purchased a total of 1,497,497 shares of company stock valued at $4,457,115 over the last three months. Corporate insiders own 0.04% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Kavi Asset Management LP bought a new position in Elanco Animal Health during the 2nd quarter valued at $3,948,000. First Republic Investment Management Inc. boosted its stake in shares of Elanco Animal Health by 3.6% during the 2nd quarter. First Republic Investment Management Inc. now owns 62,611 shares of the company’s stock worth $2,116,000 after acquiring an additional 2,171 shares in the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Elanco Animal Health by 509.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,716,444 shares of the company’s stock worth $58,016,000 after acquiring an additional 1,434,910 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Elanco Animal Health by 11.7% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,530,402 shares of the company’s stock worth $85,528,000 after acquiring an additional 265,051 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in shares of Elanco Animal Health by 390.8% during the 2nd quarter. Mackenzie Financial Corp now owns 489,520 shares of the company’s stock worth $16,546,000 after acquiring an additional 389,785 shares in the last quarter.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Story: What causes a recession?

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.